Evaluation of the
Ad mouse model
Amyloid beta oligomers
D-enantiomeric peptide
Pet probe
Preclinical
Radioligand
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
01 May 2023
01 May 2023
Historique:
received:
30
09
2022
revised:
16
02
2023
accepted:
05
03
2023
medline:
28
3
2023
pubmed:
9
3
2023
entrez:
8
3
2023
Statut:
ppublish
Résumé
Positron emission tomography (PET) imaging with radiotracers that bind to fibrillary amyloid β (Aβ) deposits is an important tool for the diagnosis of Alzheimer's disease (AD) and for the recruitment of patients into clinical trials. However, it has been suggested that rather than the fibrillary Aβ deposits, it is smaller, soluble Aβ aggregates that exert a neurotoxic effect and trigger AD pathogenesis. The aim of the current study is to develop a PET probe that is capable of detecting small aggregates and soluble Aβ oligomers for improved diagnosis and therapy monitoring. An
Identifiants
pubmed: 36889654
pii: S0928-0987(23)00052-0
doi: 10.1016/j.ejps.2023.106421
pii:
doi:
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106421Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest A.W. and D.W. are co-founders of Priavoid GmbH, Düsseldorf, Germany. A.W. is a part-time employee, and D.W. is a member of the supervisory board of Priavoid, which develops RD2 as a therapeutic compound. Priavoid holds no intellectual property concerning the development of RD2 as a diagnostic compound. All other authors declare no conflict of interest.